Form 4: Day One Biopharmaceuticals Director Acquires Stock Options

William Grossman, a director at Day One Biopharmaceuticals, acquired stock options for 32,335 shares on May 23, 2024.

Summary

• William Grossman, a director of Day One Biopharmaceuticals, Inc. (DAWN), filed a Form 4 on May 28, 2024.
• The form reports a transaction that occurred on May 23, 2024, where Grossman acquired stock options for 32,335 shares of common stock at an exercise price of $13.87.
• The options vest monthly, starting June 23, 2024, and expire on May 22, 2034.
• Following the transaction, Grossman directly owns 32,335 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director, which doesn't inherently indicate positive or negative sentiment.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's belief in the company's future.

Key Dates